Long-term effects of SARS-CoV-2 vaccination in the nursing home setting.
COVID-19
breakthrough infection
nursing home residents
older adults
vaccine
Journal
Journal of the American Geriatrics Society
ISSN: 1532-5415
Titre abrégé: J Am Geriatr Soc
Pays: United States
ID NLM: 7503062
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
02
03
2022
received:
01
12
2021
accepted:
12
03
2022
pubmed:
30
3
2022
medline:
18
5
2022
entrez:
29
3
2022
Statut:
ppublish
Résumé
SARS-CoV-2 vaccination has significantly reduced infection, hospitalization, and lethality rates among nursing home (NH) residents, but durability of vaccine effects remains unknown. This study investigated the long-term impact of BNT162b2 SARS-CoV-2 vaccine on breakthrough infection rates in the NHs of Florence, Italy. Participants included residents living in Florence NHs as of April 1st, 2021, who had completed the primary SARS-CoV2 vaccination course by February 15th, 2021. Weekly rates of breakthrough infection were calculated between April 1st and October 31st 2021, with 7-day incidence defined as the number of new confirmed SARS-CoV-2-positive residents over the vaccinated resident census. Hospital admissions and deaths were recorded from local administrative and clinical sources. Patients admitted to NHs after April 1st were excluded to avoid confounding effect of different vaccination timing. Among 2271 vaccinated residents (mean age 86.6, 74% female), we recorded 105 cases of breakthrough infections. Rates of breakthrough infection remained very low in the 6 months after vaccination, but started to rise over the following months, peaking at 0.94%, and then became stable around 0.2%-0.3%. Over the study period, infection rates remained low as compared to the incidence of SARS-CoV-2 infection during pre-vaccination period. Overall hospitalization and lethality rates were 8%. Among vaccinated NH residents, rates of breakthrough SARS-CoV-2 infection, hospitalization and lethality remained low up to 9 months following primary vaccination course. A mild resurgence of SARS-CoV-2 infection, after 6 months from vaccination, suggests a decline of vaccine effectiveness in preventing transmission.
Sections du résumé
BACKGROUND
SARS-CoV-2 vaccination has significantly reduced infection, hospitalization, and lethality rates among nursing home (NH) residents, but durability of vaccine effects remains unknown. This study investigated the long-term impact of BNT162b2 SARS-CoV-2 vaccine on breakthrough infection rates in the NHs of Florence, Italy.
METHODS
Participants included residents living in Florence NHs as of April 1st, 2021, who had completed the primary SARS-CoV2 vaccination course by February 15th, 2021. Weekly rates of breakthrough infection were calculated between April 1st and October 31st 2021, with 7-day incidence defined as the number of new confirmed SARS-CoV-2-positive residents over the vaccinated resident census. Hospital admissions and deaths were recorded from local administrative and clinical sources. Patients admitted to NHs after April 1st were excluded to avoid confounding effect of different vaccination timing.
RESULTS
Among 2271 vaccinated residents (mean age 86.6, 74% female), we recorded 105 cases of breakthrough infections. Rates of breakthrough infection remained very low in the 6 months after vaccination, but started to rise over the following months, peaking at 0.94%, and then became stable around 0.2%-0.3%. Over the study period, infection rates remained low as compared to the incidence of SARS-CoV-2 infection during pre-vaccination period. Overall hospitalization and lethality rates were 8%.
CONCLUSIONS
Among vaccinated NH residents, rates of breakthrough SARS-CoV-2 infection, hospitalization and lethality remained low up to 9 months following primary vaccination course. A mild resurgence of SARS-CoV-2 infection, after 6 months from vaccination, suggests a decline of vaccine effectiveness in preventing transmission.
Identifiants
pubmed: 35347706
doi: 10.1111/jgs.17773
pmc: PMC9115053
doi:
Substances chimiques
COVID-19 Vaccines
0
RNA, Viral
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1336-1341Subventions
Organisme : Azienda Ospedaliero-Universitaria Careggi
Organisme : Azienda USL Toscana Centro
Informations de copyright
© 2022 The Authors. Journal of the American Geriatrics Society published by Wiley Periodicals LLC on behalf of The American Geriatrics Society.
Références
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166
pubmed: 34437519
Lancet. 2021 Jul 31;398(10298):385-387
pubmed: 34274038
Aging Clin Exp Res. 2021 Oct;33(10):2917-2924
pubmed: 34417733
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1150-1155
pubmed: 34437517
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
Geriatr Nurs. 2021 Sep-Oct;42(5):1105-1108
pubmed: 34274688
J Am Med Dir Assoc. 2020 Dec;21(12):1767-1773.e1
pubmed: 33153910
Clin Infect Dis. 2021 Dec 6;73(11):2112-2115
pubmed: 33993265
N Engl J Med. 2021 Jul 29;385(5):474-476
pubmed: 34010526
Clin Infect Dis. 2021 Dec 6;73(11):2145-2147
pubmed: 33825869
Lancet Healthy Longev. 2020 Oct;1(1):e21-e31
pubmed: 34173614
Vaccines (Basel). 2021 Oct 13;9(10):
pubmed: 34696282
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
N Engl J Med. 2021 Dec 9;385(24):e83
pubmed: 34614327
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
J Am Geriatr Soc. 2022 May;70(5):1336-1341
pubmed: 35347706
J Am Med Dir Assoc. 2021 Nov;22(11):2266-2268
pubmed: 34555339
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
N Engl J Med. 2021 Sep 30;385(14):1330-1332
pubmed: 34469645
J Am Geriatr Soc. 2021 Aug;69(8):2063-2069
pubmed: 33861873
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246